Abstract: Chronic kidney disease (CKD) is a global problem which contributes to a significant morbidity and mortality in China. Concomitant inflammatory state further boosts the mortality due to cardiovascular events in patients with CKD undergoing dialysis. There is a general notion that Omega-3 fatty acids including docosahexaenoic acids (DHA) and eicosapentaenoic (EPA) have certain health benefits perhaps via the regulation of inflammation. However, the anti-inflammatory effect of omega-3 fatty acids in patients with CKD is controversial. We analyzed the data of oral supplementation of omega-3 fatty acids in CKD patients by searching literature on database from inception to August 2016. The analysis included randomized controlled trials (RCTs) derived from multiple databases, and the effect of omega-3 fatty acids supplementation versus the control cohorts were compared. All of the data analysis was calculated by RevMan 5.2. A total of 12 RCTs involving 487 patients were included in the meta-analysis. Among them 254 patients received omega-3 fatty acids and 233 patients served as controls who received placebo. The meta-analysis revealed no statistical significance in serum levels of C-reactive protein (CRP) (SMD, −0.20; 95% CI, −0.44 to 0.05; P = 0.11), IL-6 (SMD, 0.00; 95% CI, −0.33 to 0.33; P = 0.99) and TNF-α (SMD, 0.14; 95% CI, −0.17 to 0.44; P = 0.
Chronic kidney disease (CKD) is a worldwide public health problem. There is an increasing incidence and prevalence of kidney failure in CKD. Apparently, the uremic toxins in CKD patients induce inflammatory responses that are mediated by a variety of cytokines, chemokines and other inflammatory molecules. Consequentially, there is an enhanced oxidative stress and tissue injury. In such an inflammatory setting patients with CKD and those undergoing dialysis may have a higher mortality due to precipitation of undesirable cardiovascular events (1) (2) (3) . This chronic inflammatory state in patients on hemodialysis can be monitored by various serum biomarkers, such as Creactive protein (CRP), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) (4). Thus, one can envisage that the modulation of inflammatory responses may serve an important target for the treatment of CKD (5) , and efforts to prevent or attenuate inflammation would be an important step to delay the progression of CKD.
Omega-3 fatty acids (ω-3 fatty acid or n-3 fatty acid) are long-chain polyunsaturated fatty acids, which consist of α-linolenic acid (ALA, 18:3 n-3), eicosapentaenoic (EPA, 20:5 n-3) and docosahexaenoic acids (DHA, 22:6 n-3). ALA is present in vegetable oil like flaxseed, canola, olive oil, walnuts and so on, whereas EPA and DHA are found in abundance in marine oils and most fish, particularly oily ones such as tuna, salmon and trout etc. (6) . Omega-3 fatty acids are essential fatty acids since they are not synthesized in the body (7) . There is increasing evidence that suggests omega-3 fatty acids participate in the regulation of inflammation and immune response by reducing the production of monocyte pro-inflammatory cytokines, such as interleukin-1 (IL-1), IL-6 and TNF-α (8) . In addition, they can also reduce triglyceride (TG) levels (9,10) and hence the cardiovascular risk (11, 12) . In this regard, the American Heart Association (AHA) has issued guidelines for recommending daily supplementation of omega-3 fatty acids in patients with the potential to develop cardiovascular disease (13) . Likewise, Improving Global Outcomes (KDIGO) Clinical Practice Guidelines for Glomerulonephritis in 2012 (14) and the Japanese Clinical Practice Guides for IgA nephropathy (IgAN) in 2014 (15) recommended using omega-3 fatty acids in the treatment of these nephritides. In addition, the omega-3 fatty acids also reduce systemic inflammation by lowering the serum levels of TNF-α, IL-6 and CRP (16) .
However, controversies have arisen since recent studies have challenged the notion of antiinflammatory effect of omega-3 fatty acids in patients with CKD. Most of the past studies indicate that patients with CKD have low omega-3 fatty acids levels, which expectedly result in an inflammatory co-morbid state (17) . In support of this notion certain studies revealed that supplementation of omega-3 fatty acids decreases levels of inflammatory markers in hemodialysis patients (18, 19) . However, other studies report no significant effect in lowering inflammation in CKD patients treated with omega-3 fatty acids supplementation (20, 21) .
In this meta-analysis study, we examine randomized controlled trials (RCTs) while focusing on the changes in the serum concentrations of CRP, IL-6 and TNF-α following oral supplementation of omega-3 fatty acids in CKD patients, and evaluate whether or not omega-3 fatty acids improve the inflammatory state.
MATERIALS AND METHODS

Inclusion criteria
In this RCT study we compared the effect of supplementation of omega-3 fatty acids, DHA and/or EPA, on markers of inflammation between experimental subjects and the controls receiving placebo. The experimental subjects included patients with CKD receiving renal dialysis and who were dialysisindependent. The outcomes parameters included measuring the levels of serum IL-6, TNF-α and CRP. The literature studies excluded were as follows: reviews, meeting summaries, case reports, and non-clinical research articles, non-randomized controlled trials, animal research data, incorrect or incomplete data that cannot be extracted, duplicate publications or poor quality data, and studies lacking inflammatory marker data.
Search strategy
We searched the literature in PubMed, Embase, Cochrane Central Register of Controlled Trials (CCRCT) and China National Knowledge Infrastructure Database (CNKI) for clinical trials assessing the effects of omega-3 fatty acids on markers of inflammation in CKD patients from inception to August 2016. The following keywords were used: chronic renal failure (CRF), end stage renal disease (ESRD), chronic kidney disease (CKD), uremia, dialysis, hemodialysis (HD) or peritoneal dialysis; combined with omega-3 fatty acid, omega-3 polyunsaturated fatty acid, ω-3 fatty acid, n-3 fatty acid, n-3 polyunsaturated fatty acid, polyunsaturated fatty acids, fish oil, docosahexaenoic acid, eicosapentaenoic acid, DHA or EPA, and C-reactive protein, CRP, interleukin 6, IL-6, tumor necrosis factor alpha, TNF-α and inflammation. In addition, we also screened the references pertaining to the included studies with the aim of identifying potential eligibility for RCTs.
Study selection
We included RCTs analyzing oral supplementation of omega-3 fatty acids that affects inflammation parameters in patients with CKD. Two investigators reviewed all the article titles and abstracts independently. The studies that were clearly irrelevant were excluded. For articles, full-text of the articles was examined and evaluated that seem to yield a certain degree of certainty. The studies that failed to include inflammation markers were excluded. The study selection and exclusion process is shown in Figure 1 .
Data extraction and management
The data extraction was collected independently by two investigators: first author's name, study design, publication year, sample size (treatment/control), sex ratio (men/female), measurements of IL-6, TNF-α and CRP levels, duration of follow-up, treatment group (dose of n-3 PUFAs), control group (placebo or other), and kidney disease status. At the same time, the mean with 95% confidence interval was used to calculate the mean AE standard deviation (SD) (22) . The data were input to RevMan 5.2 by two investigators independently.
Study quality assessment
We used the Cochrane risk of bias guidelines (23) to assess the quality of studies, which included generation of random sequence, blinding of participants and personnel, blinding of outcome assessment, allocation concealment, incomplete outcome data as well as selective reporting, and other bias. For each study, according to the risk of bias guidelines, we designated as high risk of bias, low risk of bias or unclear risk of bias (Fig. 2 ).
Statistical analysis
For continuous results, we used mean differences (MD) with 95% confidence interval (95% CI). Since the measurement unit is different in the included RCTs, the standardized mean difference (SMD) with corresponding 95% CI to calculate continuous variables was used. Assessment of statistical heterogeneity among trials by using χ 2 and I 2 statistics was used (24) . If heterogeneity did not exist among studies, we applied a fixed-effect model to calculate pooled effect size, otherwise a random-effect model was used. In addition, the outcomes were designated statistically significant when P < 0.05.
RESULTS
Study selection
We identified records of 582 patients. Out of these, 532 irrelevant studies were excluded because of duplication identified by surveying the article's title and abstract. We further excluded 38 studies after retrieving the full texts from the remaining 50 articles. The main reason was because of being non-RCTs or not inclusive of reporting inflammatory markers. Finally, 12 studies were eligible and thus included; the details of the retrieval processes are shown in Figure 1 .
Characteristics of included studies and quality assessment
The characteristics of all the studies in this metaanalysis are shown in Table 1 . These 12 studies included a total of 487 patients, among which 254 were treated with omega-3 fatty acids and a control group included 233 treated with placebo. These studies also provided the outcomes reflected in the levels of CRP (22, (25) (26) (27) (28) (29) (30) 32, 33, 35) , IL-6 (25, (29) (30) (31) (32) (33) 35) and TNF-α (29, 31, 32, 34) . Among these, four studies included CKD patients who did not receive dialysis (22, 27, 31, 34) . The treatment studies included oral supplementation of omega-3 fatty acids at doses of 0.8-6 g/day for 2-6 months. Additionally, the risk assessments were included in these studies and they are listed in Figure 2 .
Omega-3 fatty acids and CRP
Ten studies described the effect of omega-3 fatty acid supplementation on the serum CRP levels (22, (25) (26) (27) (28) (29) (30) 32, 33, 35) . The pooled results of seven trials indicated that omega-3 fatty acids intake had no statistical difference in the levels of serum CRP (SMD, −0.20; 95% CI, −0.44 to 0.05; P = 0.11; Fig. 3) , and there was no heterogeneity among these studies (heterogeneity χ 2 = 5.92, P = 0.43, I 2 = 0%; 3 ). In the study performed by Madsen, CRP changes were calculated as median with interquartile range. The results for the group of omega-3 fatty acids supplementation and control groups were: (2.46 vs 1.47 mg/L; P = 0.06) and (3.27 vs 3.14 mg/L; P = 0 0.12), respectively (26) . Overall, it indicated that the change of serum CRP level was not different among the two groups. In another study performed by Himmelfarb et al, serum CRP data were expressed in the form of a histogram, and it also indicated no significant difference in the treatment and control group (35).
Omega-3 fatty acids and IL-6
Six studies were included pertaining to the changes in serum IL-6 levels (25, 29, (31) (32) (33) 35) . Four articles were included in the pooled analysis, which suggested that serum IL-6 levels were not significantly different in the group receiving omega-3 fatty acids supplementation compared with the controls (SMD, 0.00; 95% CI, −0.33 to 0.33; P = 0.99; Fig. 3) . A low heterogeneity was detected in these studies (heterogeneity χ 2 = 4.58, P = 0.21, I 2 = 34%; Fig. 3 ). One study performed by Himmelfarb et al. was not included in pooled analysis since it reported serum IL-6 data as a histogram (25) . However, in this study, IL-6 value was significantly reduced in the treatment group but it was not significantly different from the control group.
Omega-3 fatty acids and TNF-α
The effect of supplementation of omega-3 fatty acids on serum TNF-α level was also reported in four trials (29, 31, 32, 34) . The pooled analysis suggested that TNF-α levels had no significant differences between the experiment and control groups (SMD, 0.14; 95% CI, −0.17 to 0.44; P = 0.38; Fig. 3 ). No heterogeneity in these studies was documented (heterogeneity χ 2 = 1.8, P = 0.61, I 2 = 0%; Fig. 3 ) .
Omega-3 fatty acids affect serum IL-6, TNF-α and CRP levels in dialysis patients
We also evaluated the data of omega-3 fatty acids supplementation in dialysis patients and their effect on the serum levels of IL-6, TNF-α and CRP. The pooled analyses revealed that serum IL-6, TNF-α and CRP level were not significantly different in patients receiving omega-3 fatty acids versus the controls. The pooled respective results (Fig. 4) pertaining to serum IL-6, TNF-α and CRP levels were: 
Publication bias
We used the funnel plots to evaluate the publication bias, as shown in Figure 5 , the outcomes of serum IL-6, TNF-α and CRP were symmetric, suggesting that publication bias did not affect the result of our meta-analysis.
DISCUSSION
The meta-analysis data revealed no statistical differences in serum CRP levels between omega-3 fatty acids supplementation group and cohorts in CKD patients. Also, the serum levels of CRP and TNF-α were not statistically different between the dialysis patients receiving omega-3 fatty acids group and control group. Therefore, the current study concluded that oral supplementation of omega-3 fatty acids did not have a significant effect in reducing serum levels of IL-6, TNF-α and CRP in patients with CKD and/or those receiving dialysis. This would suggest that the omega-3 fatty acids do not exert obvious beneficial effect by reducing the inflammatory state in patents with CKD or dialysis.
Some of the recent literature reports suggest that micro-inflammation is a salient characteristic of patients with CKD in pre-dialysis or dialysis patients (36) (37) (38) , which attributes to a relatively high cardiovascular risk in such patients (39, 40) . Elevated levels of inflammatory mediators have a potential role in increasing oxidative stress and expression of advanced glycation end (AGE) products (41) . It has been reported that the progression of CKD is related to low-grade inflammation, even in patients with moderate renal dysfunction who may not be yet dialysis-dependent (42) (43) (44) , suggesting that elevation of inflammatory mediators is associated with the development of chronic renal failure. While the data of certain other recent studies indicate that the lower levels of inflammation biomarkers may rather improve the survival of CKD patients (45) (46) (47) . Therefore, modulation of micro-inflammation in patients with CKD may be of great clinical significance to delay the progression of CKD. Some of the studies indicate that omega-3 fatty acids have beneficial effect in several inflammationmediated diseases, such as Crohn's disease (48) , rheumatoid arthritis (49), IgAN (50) and various skin diseases (51) . Also, some of the review articles (7, 10) mentioned the effects of omega-3 fatty acids supplementation in CKD patients who are dialysisdependent as well as -independent. One of the problems seems to be the uremia-associated taste alterations in CKD patients undergoing hemodialysis, and as a result there would be inadequate supplementation of omega-3 fatty acids (52) . Also, hemodialysis may directly affect omega-3 fatty acids bioavailability since these patients are under increased oxidative stress, and this will result in low levels of omega-3 fatty acids (53) . Nevertheless, certain studies pertaining to endothelial biology and type 2 diabetes indicate beneficial effects of omega-3 fatty acids by modulation of inflammation (54) (55) (56) . The mechanism by which omega-3 fatty acids exert their anti-inflammatory effect may be by possibly modulating AMP-activated protein kinase (AMPK) or cellular signaling mediated via silencing information regulator1 (SIRT1); the latter apparently leads to deacetylation of nuclear factor of kappaB (NFkB) and competitive inhibition of arachidonic acid that is involved in its conversion to proinflammatory intermediaries (57) . In addition, the omega-3 fatty acids can alter the composition of cell membrane phospholipid fatty acid (58) . Furthermore, Micallef et al. reported that omega-3 fatty acids are inversely related to CRP levels in healthy individuals (59) , and they also reduce CRP and IL-6 levels in healthy older adults (60) . Likewise, omega-3 fatty acids can decrease serum CRP concentrations in various chronic diseases (61) and patients with diabetic nephropathy (62) . In addition, Tayyebi-Khosroshahi et al. also reported that omega-3 fatty acids significantly decrease the levels of TNF-α in hemodialysis patients (63) . However, other studies indicated no significant effect on the inflammatory state in CKD patients with supplementation of omega-3 fatty acids (20, 21) . The present meta-analysis study indicates that there are no significant differences in serum IL-6, TNF-α and CRP levels between the untreated and patients treated with omega-3 fatty acids supplementation. This could be due to several variables, including the study duration, the number of studied patients, EPA/DHA ratios and dosage of omega-3 fatty acids used, as well as the baseline levels of inflammation markers. In addition, the existing medical status or a given patient undergoing other treatments may be additional factors influencing the outcome (64). Another reason for the failure of omega-3 fatty acids supplementation to reduce inflammation in CKD/HD patients may due to the extent of inflammatory response which may be too strong to be overcome by the anti-inflammatory effect of omega-3 fatty acids in CKD, especially those patients undergoing hemodialysis.
In terms of side-effects of omega-3 fatty acids in CKD patients, there have been three trials reported in the literature (31, 33) . The meta-analysis of these studies indicated no obvious alarming side effects related to omega-3 fatty acids supplementation. Our meta-analysis study also included a report by Saifullah et al. (26) , which indicated minimal gastrointestinal disturbances in the group of patients taking fish oil. Also, none of the patients discontinued the omega-3 fatty acids supplementation due to these minor gastrointestinal side-effects.
Finally, although meta-analysis was carefully performed in this study, there may be certain limitations.
Primarily, this may be due to the trial size being relatively small. In this regard, a total of 12 RCTs involving 487 patients were included in this meta-analysis; with seven studies included in pooled analysis pertaining to the change in serum CRP levels, while four studies described the changes in serum levels of both IL-6 and TNF-α. Secondly, some of the included studies were not double-blinded. Thirdly, some of the results were described as median and range, while others in the form of histograms which could not be included in the meta-analysis. Finally, there was lack of long-term follow-up acids about the effect of omega-3 fatty acids supplementation in CKD patients on inflammatory markers.
CONCLUSION
The present meta-analysis indicates that there is insufficient evidence that provides a statistically significant benefit of omega-3 fatty acids supplementation on serum inflammation biomarkers, including C-reactive protein, TNF-α and IL-6 levels in patients with chronic kidney disease. Further large-scale and longterm clinical trials are needed to arrive at concrete conclusions.
